In Part A, there was one partial response (PR), in a patient with V600E BRAF-mutated papillary thyroid cancer (KRAS-WT, PTEN weakly reactive) receiving E6201 480 mg/m2, who had a response for four cycles. Here, KRAS is linked to thyroid gland papillary carcinoma.